Kite Pharma, Changing the Way Cancer is Treated
Kite is dedicated to curing cancer. Learn about the science of cell therapy, our cancer research, and our cancer treatments in the pipeline.
Careers at Kite - Kite Pharma
Everyone at Kite is grounded by one common goal – curing cancer. Our personalized approach is what sets us apart from other health and life science companies. Unlike traditional pharmaceutical manufacturing, our therapies are not created on an assembly line.
Kite Pharma - Wikipedia
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells.
Our Focus on Cell Therapy | Kite Pharma
Founded in 2009 and acquired by Gilead Sciences in 2017, Kite has been a pioneer in cell therapy research and leader in the immuno-oncology space.
Gilead Sciences to Acquire Kite Pharma for 119 Billion
Aug 28, 2017 · FOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Kite Pharma, Inc. (Nasdaq: KITE) announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Kite for $180.00 per share in cash.
Gilead to lay off staff at cell therapy unit Kite
Nov 29, 2023 · Kite is a leading producer of CAR-T cell therapies, which involve the engineering of a patients’ own immune cells to better fight cancer. Yescarta was the unit’s first approved, and recently received an expanded clearance in the U.S. for earlier use treating lymphoma.
Kite Pharma - LinkedIn
At Kite, a Gilead Company, our singular focus is achieving cures with cell therapy. Our goal is to bring the promise of cell therapy to as many eligible patients as possible who may benefit....
Gilead to buy Kite for promising cancer therapies in $12 billion deal
Aug 28, 2017 · Gilead Sciences Inc agreed to buy Kite Pharma Inc in a nearly $12 billion deal on Monday, as it looks to replace flagging sales from hepatitis C drugs with an emerging and expensive class of...
Gilead’s Kite shortens Yescarta manufacturing time with FDA nod
Jan 30, 2024 · The FDA has approved a new manufacturing process change for Yescarta, Gilead’s Kite Pharma unit said Tuesday. The approval allows the company to shorten the CAR-T cell manufacturing time for ...
Transformational Cancer Treatment - Kite Pharma
Learn about Kite’s mission to change the way cancer is treated with cell therapy – the use of genetically modified immune cells programmed to target tumors.